Adderall XR Cost in Montana 2026: Cash Price, Insurance, and Compounded Options

What Does Adderall XR Actually Cost in Montana Right Now?

The average retail cash price for generic mixed amphetamine salts extended-release in Montana is approximately $30 per month in 2026, based on pharmacy benefit data aggregated across independent and chain pharmacies in the state. That figure applies to a standard 30-capsule supply at a commonly prescribed dose such as 20 mg or 30 mg. The brand-name Adderall XR carries a list price closer to $260 per month, but almost no cash-pay patient fills brand-name when generics are on shelf.

Prices shift depending on the specific dose, the pharmacy, and whether a discount card is applied. A 10 mg generic capsule often runs lower than a 30 mg capsule because of demand-weighted pricing. Independent rural pharmacies in places like Billings, Missoula, and Great Falls may price slightly differently from national chains. Checking GoodRx or a similar aggregator before filling at any specific location can save $5 to $15 per fill.

The shortage of amphetamine salts that began in 2022 has eased somewhat through 2025 and into 2026, though DEA manufacturing quotas for Schedule II stimulants still constrain supply at times. The FDA tracks amphetamine shortage status in real time. Supply gaps can temporarily push cash prices up at pharmacies with lower stock, so checking availability at two or three local pharmacies remains practical advice.

How Montana Medicaid Treats Adderall XR

Montana Medicaid does not cover Adderall XR on its current preferred drug list. This means members enrolled in Medicaid or the Montana Children's Health Insurance Program (CHIP) cannot get brand-name or generic mixed amphetamine salts XR reimbursed without a successful prior authorization appeal, which is rarely granted for this formulation.

Medicaid in Montana does cover some immediate-release amphetamine-based ADHD medications, and coverage rules change annually with the state formulary update. Patients on Medicaid should ask their prescriber to check the current Montana Medicaid preferred drug list directly before assuming any amphetamine product is excluded. The Montana DPHHS updates formulary documents each fiscal year. For federal Medicaid policy context, the CMS guidance on mental health parity is relevant: 42 CFR Part 438.

Children with ADHD who rely on Medicaid coverage face the biggest access gap here. The landmark MTA Cooperative Group study (N=579, Arch Gen Psychiatry 1999) demonstrated that carefully managed medication treatment produced significantly larger reductions in ADHD symptoms at 14 months compared to behavioral therapy alone or community care, establishing stimulant medication as the evidence anchor for ADHD management. That study is indexed at PubMed. When medication access is blocked by formulary exclusions, those outcomes are at risk.

Patients denied coverage may pursue a formal grievance or exception request through the Montana Medicaid managed care organization. Getting a letter of medical necessity from the prescriber that cites functional impairment, prior treatment failures, and peer-reviewed efficacy data strengthens that appeal.

Commercial Insurance and Prior Authorization in Montana

Most private insurance plans sold in Montana, whether through the ACA marketplace, employer groups, or direct commercial carriers, cover generic mixed amphetamine salts XR but require prior authorization. The process typically asks the prescriber to document the patient's ADHD diagnosis, confirm age-appropriate diagnostic criteria were applied, list any prior medication trials, and certify that the requested dose is within FDA-labeled guidelines.

The FDA-approved label for Adderall XR specifies a maximum dose of 30 mg per day for adults with ADHD and 20 mg per day for pediatric patients ages 6 to 12. The full prescribing information is available through FDA AccessData. Requests that stay within those labeled dose ranges face fewer insurer objections.

Step therapy requirements are common. An insurer may require a trial of immediate-release amphetamine salts or methylphenidate before approving the extended-release formulation. This can delay access by 30 to 90 days while step therapy is documented. Prescribers can request a step-therapy override if the patient has a documented intolerance, an occupational requirement for once-daily dosing, or a prior failed trial.

Once approved, copays on commercial plans in Montana generally range from $10 to $45 per month for the generic. Plans with high-deductible structures may charge the full negotiated rate, which sits between the $30 cash price and the $260 list price depending on the pharmacy benefit manager's contract.

Compounded Mixed Amphetamine Salts in Montana: What Is Legal

Compounded mixed amphetamine salts are legal to prepare and dispense in Montana through licensed 503A compounding pharmacies operating under state pharmacy board oversight and the federal Drug Quality and Security Act. The 503A designation means the pharmacy compounds for individual patients based on a valid, patient-specific prescription. This is not the same as a 503B outsourcing facility, which can manufacture larger batches.

The legal pathway is clear. A Montana-licensed prescriber writes a prescription for a compounded amphetamine formulation specifying the exact dose, salt form, and release profile. A licensed 503A pharmacy then fills it. The DEA still classifies amphetamine as Schedule II, so the same controlled substance rules apply: no refills, written or electronic prescriptions only, 30-day supply limits.

The practical cost picture differs from retail generics. Several telehealth and direct-care platforms have arrangements with 503A pharmacies where the compounded product is included in a membership fee, which can reduce the effective out-of-pocket cost to $0 per month for the medication itself. Whether that model makes financial sense depends on the membership cost and the patient's insurance situation.

Compounded formulations are not FDA-approved as finished drug products. The FDA does not review the safety, efficacy, or consistency of compounded preparations the way it does for approved generics. Patients should verify that any compounding pharmacy they use is licensed by the Montana Board of Pharmacy and in good standing with the state.

Telehealth Prescribing of Adderall XR in Montana

Telehealth prescribing of Schedule II controlled substances, including Adderall XR, is legal in Montana for established patients under DEA special registration rules that took effect through 2024. The DEA's telehealth prescribing framework, extended and clarified in late 2023, allows a practitioner with a valid DEA registration in Montana to prescribe Schedule II stimulants via synchronous audio-video telehealth if the patient has previously established care with that provider.

Montana does not impose additional state-level restrictions beyond federal DEA rules for this medication category, making it one of the more accessible states for telehealth ADHD care. Prescriptions must still be transmitted as electronic prescriptions for controlled substances (EPCS) to a Montana-licensed pharmacy.

Patients in rural Montana counties, where the nearest psychiatrist or ADHD specialist may be hours away, benefit most from this access. The American Academy of Family Physicians supports telehealth expansion for ADHD management as part of primary care, noting that access barriers disproportionately affect rural populations. AAFP policy positions are published at aafp.org.

A telehealth ADHD evaluation that results in an Adderall XR prescription typically costs $100 to $250 for the initial visit through a dedicated ADHD telehealth platform. Follow-up visits are often $50 to $99. Those costs are separate from the prescription fill price.

Why the Gap Between List Price and Cash Price Is So Large

The $260 list price and the $30 cash price coexist because pharmacy benefit manager rebate negotiations, generic competition, and discount aggregator networks all work on different layers of the drug pricing system. Teva, the primary generic manufacturer, holds a significant share of the mixed amphetamine salts XR market alongside Shire (now AbbVie) for brand Adderall XR.

When a patient pays cash without insurance and uses a discount card from GoodRx, NeedyMeds, or a pharmacy's own savings program, the pharmacy dispenses at a contracted rate that can be as low as $25 to $35 for a 30-count, 20 mg supply. That contract rate bears no relationship to the list price, which exists primarily as the starting point for PBM rebate negotiations.

The net price insurers pay after rebates is not publicly disclosed. What is public: the average manufacturer price (AMP) filed with CMS and the Medicaid drug rebate data, which show that generic amphetamine salts have among the lowest net prices in the stimulant class. CMS drug pricing data is published at medicaid.gov.

Patients who pay cash should never fill at list price. Presenting a GoodRx or similar coupon at the pharmacy counter, even when not using insurance, typically yields the $30 range price. The pharmacist applies the discount card's contracted rate at the register.

Savings Programs Available to Montana Residents

Several assistance mechanisms exist for patients in Montana who face cost barriers.

Manufacturer patient assistance. Teva does not operate a strong branded Adderall XR coupon program because the product is primarily generic, but AbbVie's patient assistance portal covers brand Adderall XR for patients below certain income thresholds. Applications go through NeedyMeds or directly through the manufacturer.

GoodRx and similar aggregators. These are not insurance but function as discount contracts with participating pharmacies. In Montana, virtually every chain pharmacy accepts GoodRx pricing. The app shows real-time pricing at Walmart, Walgreens, CVS, and local independent pharmacies. A 30-count, 20 mg generic fill through GoodRx at Walmart in Montana was showing prices near $22 to $35 in early 2026, depending on location.

Montana CHIP and CHIP wrap programs. For children who qualify but whose Medicaid formulary excludes Adderall XR, some CHIP supplemental programs allow formulary exceptions more easily than standard Medicaid. A pediatric prescriber familiar with the Montana CHIP formulary can guide families through this.

340B program pharmacies. Federally qualified health centers in Montana participate in the 340B drug pricing program, which gives them access to deeply discounted drug costs they can pass to uninsured or underinsured patients. 340B program details are at hrsa.gov. Patients receiving care at an FQHC in Montana may access Adderall XR at or near the 340B price, which can be below $15 per month.

Free samples. Because Adderall XR is generic and off-patent, manufacturer samples are essentially nonexistent. Some 503A compounding pharmacies offer a trial supply of a compounded formulation as part of an onboarding program, but this varies by pharmacy.

Clinical Context: Why Adderall XR and Not Immediate-Release?

Adderall XR uses a beaded dual-delivery system: approximately 50 percent of the mixed amphetamine salts release immediately and 50 percent release 4 hours later, producing a smooth 10 to 12-hour effect duration from a single morning dose. The pharmacokinetic data supporting this design are included in the FDA label. Immediate-release Adderall requires two or three daily doses to achieve comparable coverage, which raises adherence complexity and increases the risk of afternoon rebound symptoms.

For adults managing workplace responsibilities and for school-age children needing coverage through after-school hours, the extended-release profile offers a real clinical advantage. As the MTA Cooperative Group stated in their 1999 report: "Carefully titrated medication management was superior to behavioral treatment and to routine community care." PubMed PMID 10591282. That superiority rests on adequate duration of action throughout the functional day, which once-daily XR dosing supports better than twice-daily IR in most patients.

The FDA-approved dose range for adults with ADHD starts at 20 mg once daily. Doses above 30 mg per day are not recommended in labeling, though clinical practice sometimes exceeds this in adults under specialist supervision with documented rationale. Starting dose for children ages 6 and older is 5 mg to 10 mg, titrated in 5 mg to 10 mg increments at weekly intervals.

Comparing Your Cost Options Side by Side

To make the cost picture concrete, consider a 35-year-old Montana adult prescribed Adderall XR 20 mg once daily:

• Cash price at retail pharmacy with GoodRx: approximately $28 to $35 per month.
• Brand-name Adderall XR at list price (no discounts): approximately $260 per month.
• Commercial insurance with prior authorization, generic, $20 copay: approximately $20 per month after deductible is met.
• Montana Medicaid: not covered; patient pays full cash price.
• 503A compounded mixed amphetamine salts through a telehealth platform with inclusive membership: potentially $0 for the medication, but membership fees of $99 to $199 per month may apply.
• 340B FQHC pharmacy, uninsured patient: potentially $10 to $15 per month.

The cheapest route for most uninsured Montana adults without FQHC access is the GoodRx cash-pay path at a Walmart or Costco pharmacy, which consistently quotes the lowest contracted prices in the state.

Dose Titration and What to Expect the First Month

Starting Adderall XR at the lowest effective dose keeps both side-effect burden and cost manageable. At 20 mg, most adults with ADHD notice meaningful symptom improvement within the first two to three days. Full benefit assessment typically takes two to four weeks of consistent morning dosing.

Common early side effects include appetite suppression, mild insomnia if taken too late in the day, and a slight increase in resting heart rate (typically 3 to 7 beats per minute in clinical trials). The FDA label advises monitoring blood pressure and heart rate at baseline, after the first dose increase, and at each follow-up visit. Patients with pre-existing hypertension or a history of structural cardiac abnormalities require cardiology clearance before starting any amphetamine product.

If the initial 20 mg dose is insufficient after two weeks, the prescriber may increase to 25 mg or 30 mg. Each dose step may require a new prior authorization submission if the insurer tied approval to a specific dose. Documenting the titration rationale in the chart at each visit reduces friction in that process.

A 30-day first prescription at 20 mg costs approximately $30 cash in Montana. If a dose increase to 30 mg is needed after the first month, prices at the 30 mg strength are typically similar or slightly higher, often $30 to $40 per month cash.